<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352975</url>
  </required_header>
  <id_info>
    <org_study_id>110147</org_study_id>
    <secondary_id>11-EI-0147</secondary_id>
    <nct_id>NCT01352975</nct_id>
  </id_info>
  <brief_title>Study of Dark Adaptation in Age-Related Macular Degeneration</brief_title>
  <official_title>Longitudinal Investigation of Dark Adaptation in Participants With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals&#xD;
           over 55 years of age. It can cause permanent loss of central vision, which is important&#xD;
           for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most&#xD;
           people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more&#xD;
           serious form and can result in severe vision loss.&#xD;
&#xD;
        -  A method to identify and monitor the early to middle stages of AMD may help researchers&#xD;
           develop new treatments to stop the disease before it becomes severe. In early dry AMD,&#xD;
           people cannot see well at night. Researchers want to study whether a procedure that&#xD;
           measures how the eye adjusts to the dark can help to identify and monitor early to&#xD;
           middle dry AMD.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor&#xD;
      early to middle dry age-related macular degeneration.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - People at least 50 years of age who have no AMD. Others who have early to middle dry AMD in&#xD;
      at least one eye.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  People will be screened with a physical examination, medical history, blood and urine&#xD;
           tests, and a full eye exam.&#xD;
&#xD;
        -  This study will last 5 years and require at least 9 visits to NIH. (First visit; study&#xD;
           visits at months 3, 6, 12, 18, and 24; and 3 yearly followup visits).&#xD;
&#xD;
        -  Up to 10 people will be asked to come back to the clinic 1 week after their first visit.&#xD;
           They will be asked to test the device to be used in the study.&#xD;
&#xD;
        -  Participants will have baseline exams. These questions will be about problems that&#xD;
           affect their eyes under different lighting conditions.&#xD;
&#xD;
        -  At every visit, participants will answer questions about general health and current&#xD;
           medications (including any vitamins or supplements). They will also have a full eye exam&#xD;
           and a 20- to 40-minute test. This test measures how fast the eyes recover in response to&#xD;
           decreasing levels of light. The test also measures how sensitive the eyes are to these&#xD;
           conditions.&#xD;
&#xD;
        -  Participants will continue to have these tests at the yearly followup examinations. They&#xD;
           will be treated with the standard of care for any eye conditions they have or may&#xD;
           develop during the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This study is designed to investigate the use of dark adaptation as a functional&#xD;
      endpoint for progression of eyes with no to intermediate age-related macular degeneration&#xD;
      (AMD). To that aim, correlating structural features (obtained from multimodal imaging) as&#xD;
      well as genetic and systemic factors obtained from biospecimens with functional measures&#xD;
      (including dark adaptation, visual acuity and low luminance) will be done to understand the&#xD;
      relationship of disease relevant factors and to create a model of disease pathogenesis and&#xD;
      progression.&#xD;
&#xD;
      Study Population: Two hundred forty (240) participants will be initially accrued; however, up&#xD;
      to 280 participants who meet the eligibility criteria may be enrolled. Participants will have&#xD;
      varying degrees of severity of AMD (Groups 0, 1, 2, 3 and 4). Group 0 (N=40) is defined as&#xD;
      participants without AMD meaning no large drusen (greater than or equal to 125 microns) or&#xD;
      advanced AMD in either eye. Group 1 (N=40) is defined as participants with large drusen&#xD;
      (greater than or equal to 125 microns) in the study eye and no large drusen or advanced AMD&#xD;
      (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye. Group 2&#xD;
      (N=40) is defined as participants with bilateral large drusen (greater than or equal to 125&#xD;
      microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes. Group 3&#xD;
      (N=40) is defined as participants with large drusen (greater than or equal to 125 microns) in&#xD;
      the study eye and advanced AMD (CNV or GA) in the fellow eye. Group 4 (N=40) is defined as&#xD;
      participants with findings of reticular pseudodrusen (RPD) defined as having (1) the presence&#xD;
      of reticular inter-lacing patterns on at least one en face imaging method (color photography,&#xD;
      autofluorescence or infrared) and (2) confirmation of previously described findings of&#xD;
      hyperreflective material located between the retinal pigment epithelium (RPE) and the&#xD;
      photoreceptor ellipsoid zone on SD OCT in those areas. Current participants in this study&#xD;
      have been graded and categorized into this cohort. Up to 40 diabetic participants will be&#xD;
      recruited.&#xD;
&#xD;
      Design: This is a single center, exploratory, observational, longitudinal evaluation of dark&#xD;
      adaptation response in AMD participants over five years and long-term evaluation of dark&#xD;
      adaptometry (DA) change as a predictor for AMD progression and visual acuity (VA) loss.&#xD;
&#xD;
      Outcome Measures: The primary outcome is to determine mean change, including the distribution&#xD;
      of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0, 1,&#xD;
      2, 3 and 4. The secondary outcomes for each of the five groups are to determine mean change&#xD;
      in dark adaptation response from baseline at months 3, 6, 18, 36, 48 and 60 and to determine&#xD;
      mean change in best-corrected visual acuity (BCVA) of the study eye from baseline at months&#xD;
      3, 6, 12, 18, 24, 36, 48 and 60. Exploratory outcomes for each of the five groups are to&#xD;
      correlate mean BCVA of the study eye with mean dark adaptation response at baseline and&#xD;
      months 3, 6, 12, 18, 24, 36, 48 and 60 and to correlate AMD severity, including grading by an&#xD;
      external Reading Center, with dark adaptation response at baseline and months 3, 6, 12, 18,&#xD;
      24, 36, 48 and 60. Images from all visits may be sent to the Reading Center; however, only&#xD;
      the baseline and annual visits are required to be graded. This study will also analyze renal&#xD;
      function in AMD participants. Additionally, exploratory analysis of the small sample of&#xD;
      diabetic participants will also be performed.&#xD;
&#xD;
      Outcome measures for the genetic testing and RNA sequencing performed on participants&#xD;
      co-enrolled in the Biobank protocol (12-EI-0042) include the interaction of key parameters of&#xD;
      phenotype (such as visual acuity, dark adaptation, and retinal features on ocular imaging)&#xD;
      with genetic variants and other biomarkers identified from biospecimens, and the&#xD;
      characterization of new experimental models of eye health and disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is to determine mean change, including the distribution of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0 - 4.</measure>
    <time_frame>Month 12 and Month 24</time_frame>
    <description>mean change, including the distribution of change, in dark adaptation response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine mean change in dark adaptation response from baseline at months 3, 6, 18, 36, 48 and 60 .</measure>
    <time_frame>Months 3, 6, 18, 36, 48 and 60</time_frame>
    <description>mean change in DA response from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine mean BCVA of the study eye from baseline at months 3, 6, 12, 18, 24, 36, 48 and 60.</measure>
    <time_frame>Months 3, 6, 12, 18, 24, 36, 48 and 60</time_frame>
    <description>mean BCVA of study eye from baseline</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Group 0</arm_group_label>
    <description>participants without AMD (no large drusen or advanced AMD in either eye)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>participants with large drusen in study eye and no large drusen or advanced AMD or GA in fellow eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>participants with bilateral large drusen with or without retinal pigment epithelial hypo/hyperpigmentary changes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>participants with large drusen in study eye and advanced AMD (CNV and GA) in fellow eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>participants with findings of RPD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Two hundred forty participants (240) will be initially accrued; however, up to 280&#xD;
        participants who meet the eligibility criteria may be enrolled. In the event that a&#xD;
        participant withdraws from the study prior to month 12, an additional participant will be&#xD;
        accrued. A maximum of 40 non-diabetic participants per group will be accrued in order to&#xD;
        obtain 200 non-diabetic participants for the primary outcome analysis. Every effort will be&#xD;
        made to ensure 40 non-diabetic participants per group are accrued. Additionally, a maximum&#xD;
        of 40 diabetic participants will be accrued across all groups for the exploratory outcome&#xD;
        analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Participants will be eligible if the following inclusion criteria are met:&#xD;
&#xD;
          -  Participant is able to understand and sign the protocol s informed consent document.&#xD;
&#xD;
          -  Participant is able to complete and comply with study assessments for the full&#xD;
             duration of the study.&#xD;
&#xD;
          -  Participant is greater than or equal to 50 years of age.&#xD;
&#xD;
          -  Participant has a BCVA score of greater than or equal to 20/100 (Snellen equivalent)&#xD;
             in study eye.&#xD;
&#xD;
          -  Participant qualifies for one of the following groups based on AMD grading as defined&#xD;
             below.&#xD;
&#xD;
               -  Group 0: Participant without AMD defined as no large drusen or advanced AMD in&#xD;
                  either eye;&#xD;
&#xD;
               -  Group 1: Participant has at least one large drusen (greater than or equal to 125&#xD;
                  microns) in the study eye and no large drusen or advanced AMD in the fellow eye;&#xD;
&#xD;
               -  Group 2: Participant has bilateral large drusen (greater than or equal to 125&#xD;
                  microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes;&#xD;
&#xD;
               -  Group 3: Participant has at least one large drusen (greater than or equal to 125&#xD;
                  microns) in the study eye and advanced AMD in the fellow eye.&#xD;
&#xD;
               -  Group 4: Participant has reticular pseudodrusen in the study eye defined as&#xD;
                  having the presence of RPD on at least one en face imaging method (color&#xD;
                  photography, autofluorescence or infrared) and (2) confirmation of previously&#xD;
                  described findings of hyperreflective material located between the RPE and the&#xD;
                  photoreceptor ellipsoid zone on SD OCT in those areas.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          -  Participant has advanced AMD in the study eye at the baseline visit.&#xD;
&#xD;
          -  Participant has other active ocular or macular diseases (e.g., diabetic macular edema,&#xD;
             retinal vein occlusion, Stargardt s disease or cone-rod dystrophy) or other known&#xD;
             ocular disorders that have caused a visual field deficit (e.g., glaucoma with known&#xD;
             visual field defect) in the study eye.&#xD;
&#xD;
          -  Participant has a fixation deficit in the study eye that would prevent the participant&#xD;
             from performing the AdaptDxTM dark adaptation protocol.&#xD;
&#xD;
          -  Participant has a medical condition that the investigator feels would prevent the&#xD;
             participant from complying with or being able to complete the study assessments&#xD;
&#xD;
          -  Participant had cataract surgery in the study eye within three months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Participant has an oral intake of high doses of vitamin A palmitate supplement&#xD;
             (greater than or equal to 10,000 international units (IU) per day).&#xD;
&#xD;
          -  Participant has or had hepatitis or liver disease. Abnormally low vitamin A can alter&#xD;
             dark adaptation and chronic liver disease has been associated with low vitamin A.&#xD;
&#xD;
          -  Participant has a history of vitamin A deficiency.&#xD;
&#xD;
          -  Participant is an NEI employee or subordinate or co-worker of an investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine A Cukras, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel H Garced, R.N.</last_name>
    <phone>(301) 594-3141</phone>
    <email>garceda@nei.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine A Cukras, M.D.</last_name>
    <phone>(301) 435-5061</phone>
    <email>cukrasc@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2011-EI-0147.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640-2.</citation>
    <PMID>6208888</PMID>
  </reference>
  <reference>
    <citation>Friedman DS, O'Colmain BJ, Mu√±oz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564-72. Erratum in: Arch Ophthalmol. 2011 Sep;129(9):1188.</citation>
    <PMID>15078675</PMID>
  </reference>
  <reference>
    <citation>Scilley K, Jackson GR, Cideciyan AV, Maguire MG, Jacobson SG, Owsley C. Early age-related maculopathy and self-reported visual difficulty in daily life. Ophthalmology. 2002 Jul;109(7):1235-42.</citation>
    <PMID>12093644</PMID>
  </reference>
  <reference>
    <citation>Grune T, Lietz G, Palou A, Ross AC, Stahl W, Tang G, Thurnham D, Yin SA, Biesalski HK. Beta-carotene is an important vitamin A source for humans. J Nutr. 2010 Dec;140(12):2268S-2285S. doi: 10.3945/jn.109.119024. Epub 2010 Oct 27.</citation>
    <PMID>20980645</PMID>
  </reference>
  <verification_date>November 10, 2021</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dark Adaptation</keyword>
  <keyword>Age-Related Macular Degeneration (AMD)</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

